Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of OATP Inhibition on the Single Dose Pharmacokinetics of PF-07328948 in Healthy Adult Participants.

NCT06837259 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06837259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06837259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of OATP Inhibition on the Single Dose Pharmacokinetics of PF-07328948 in Healthy Adult Participants.
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
March 19, 2025
Completion date
June 11, 2025
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adults